Cargando…

Pathological Changes in the Lungs of Patients with a Lethal COVID-19 Clinical Course

The novel coronavirus SARS-CoV-2 was identified in 2019 and quickly became the cause of the fifth worst pandemic in human history. Our goal for this research paper was to examine the morphology of the lungs in 88 patients that died from COVID-19 in Latvia, thus increasing the data available about th...

Descripción completa

Detalles Bibliográficos
Autores principales: Viksne, Valters, Strumfa, Ilze, Sperga, Maris, Ziemelis, Janis, Abolins, Juris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689224/
https://www.ncbi.nlm.nih.gov/pubmed/36428868
http://dx.doi.org/10.3390/diagnostics12112808
_version_ 1784836477395402752
author Viksne, Valters
Strumfa, Ilze
Sperga, Maris
Ziemelis, Janis
Abolins, Juris
author_facet Viksne, Valters
Strumfa, Ilze
Sperga, Maris
Ziemelis, Janis
Abolins, Juris
author_sort Viksne, Valters
collection PubMed
description The novel coronavirus SARS-CoV-2 was identified in 2019 and quickly became the cause of the fifth worst pandemic in human history. Our goal for this research paper was to examine the morphology of the lungs in 88 patients that died from COVID-19 in Latvia, thus increasing the data available about the histological characteristics of SARS-CoV-2-induced disease. Lung tissue samples from 88 autopsies were visualized in hematoxylin–eosin and assessed by light microscopy. The male-to-female ratio was 56:32, and the mean age was 62 years ± 15.5 years (22–94 years). Clinically important laboratory data were assessed, including leucocyte count, CRP (C-reactive protein) and D-dimer levels. Signs of diffuse alveolar damage were found in 83/88 (94.3%; 95% CI 87.0–97.9) of patients, 38/88 (43.2%; 95% CI 33.3–53.6) in the exudative phase, and 45/88 (51.1%; 95% CI 40.8–61.3) in the proliferative phase. Vascular damage was identified in 70/88 (79.5%; 95% CI 69.9–86.7) of patients, and 83/88 (94.3%; 95% CI 87.0–97.9) had signs of thrombosis. A sparse inflammatory infiltrate of lymphocytes and macrophages was a common finding aside from cases with an identified coinfection. Eighty patients had significant co-morbidities, including coronary heart disease (49), primary arterial hypertension (41), and diabetes mellitus (34). Since our group’s demographic profile and spectrum of co-morbidities were analogous to other reports, the histological findings of marked diffuse alveolar damage, widespread vascular lesions, and active thrombosis can be considered representative of severe COVID-19.
format Online
Article
Text
id pubmed-9689224
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96892242022-11-25 Pathological Changes in the Lungs of Patients with a Lethal COVID-19 Clinical Course Viksne, Valters Strumfa, Ilze Sperga, Maris Ziemelis, Janis Abolins, Juris Diagnostics (Basel) Article The novel coronavirus SARS-CoV-2 was identified in 2019 and quickly became the cause of the fifth worst pandemic in human history. Our goal for this research paper was to examine the morphology of the lungs in 88 patients that died from COVID-19 in Latvia, thus increasing the data available about the histological characteristics of SARS-CoV-2-induced disease. Lung tissue samples from 88 autopsies were visualized in hematoxylin–eosin and assessed by light microscopy. The male-to-female ratio was 56:32, and the mean age was 62 years ± 15.5 years (22–94 years). Clinically important laboratory data were assessed, including leucocyte count, CRP (C-reactive protein) and D-dimer levels. Signs of diffuse alveolar damage were found in 83/88 (94.3%; 95% CI 87.0–97.9) of patients, 38/88 (43.2%; 95% CI 33.3–53.6) in the exudative phase, and 45/88 (51.1%; 95% CI 40.8–61.3) in the proliferative phase. Vascular damage was identified in 70/88 (79.5%; 95% CI 69.9–86.7) of patients, and 83/88 (94.3%; 95% CI 87.0–97.9) had signs of thrombosis. A sparse inflammatory infiltrate of lymphocytes and macrophages was a common finding aside from cases with an identified coinfection. Eighty patients had significant co-morbidities, including coronary heart disease (49), primary arterial hypertension (41), and diabetes mellitus (34). Since our group’s demographic profile and spectrum of co-morbidities were analogous to other reports, the histological findings of marked diffuse alveolar damage, widespread vascular lesions, and active thrombosis can be considered representative of severe COVID-19. MDPI 2022-11-15 /pmc/articles/PMC9689224/ /pubmed/36428868 http://dx.doi.org/10.3390/diagnostics12112808 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Viksne, Valters
Strumfa, Ilze
Sperga, Maris
Ziemelis, Janis
Abolins, Juris
Pathological Changes in the Lungs of Patients with a Lethal COVID-19 Clinical Course
title Pathological Changes in the Lungs of Patients with a Lethal COVID-19 Clinical Course
title_full Pathological Changes in the Lungs of Patients with a Lethal COVID-19 Clinical Course
title_fullStr Pathological Changes in the Lungs of Patients with a Lethal COVID-19 Clinical Course
title_full_unstemmed Pathological Changes in the Lungs of Patients with a Lethal COVID-19 Clinical Course
title_short Pathological Changes in the Lungs of Patients with a Lethal COVID-19 Clinical Course
title_sort pathological changes in the lungs of patients with a lethal covid-19 clinical course
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689224/
https://www.ncbi.nlm.nih.gov/pubmed/36428868
http://dx.doi.org/10.3390/diagnostics12112808
work_keys_str_mv AT viksnevalters pathologicalchangesinthelungsofpatientswithalethalcovid19clinicalcourse
AT strumfailze pathologicalchangesinthelungsofpatientswithalethalcovid19clinicalcourse
AT spergamaris pathologicalchangesinthelungsofpatientswithalethalcovid19clinicalcourse
AT ziemelisjanis pathologicalchangesinthelungsofpatientswithalethalcovid19clinicalcourse
AT abolinsjuris pathologicalchangesinthelungsofpatientswithalethalcovid19clinicalcourse